Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


Merck India: Restructuring drives growth

(Dec 30, 2003)

Merck India is a 51% subsidiary of Merck KgaA, Germany. The company derives almost 60% of its revenues from its pharmaceutical business and the balance from chemicals. The company’s pharmaceutical business comprises mainly of vitamins, cardio-vascular drugs, and cough and cold preparation. The chemical business on the other hand, comprises of analytics, reagents, scientific laboratory products and pigments.

E.Merck: Healthy performance

(Apr 5, 2002)

E.Merck (India), the subsidiary of the German multinational Merck, reported encouraging numbers for the year ended Dec' 01 (FY02). A topline growth of 8% reported by the company is comparatively better than the performance of other MNC pharma peers. Both sales and operating margins improved on the back of upward price revision and relaunch of its vitamin brand Neurobion in June 2000.

E.Merck: Shifting focus

(Sep 18, 2001)

E.Merck (India), subsidiary of the German multinational Merck, reported a healthy topline performance for 2QFY02. While the company managed to log double digit topline growth operating margins were under pressure. The growth in sales is primarily due to an upward price revision in its vitamin brand Neurobion in June 2000.

A strong dose from E. Merck

(Oct 19, 2000)

E. Merck has reported impressive results for the third quarter ended September 2000 with a net profit growth of 62.75% to Rs 118.36 m (from a level of Rs 72.72 m in the second quarter). This is on the back of a 16.48% rise in the net sales to Rs 744.30 m. Interest expenditure has gone down almost 76% to Rs 3.73 m.

E. Merck: The vitamin king consolidates

(Sep 30, 2000)

E. Merck is the market leader in vitamins and derives over 60% of its turnover from this segment. Three of its vitamin brands Evion, Neurobion and Polybion contribute almost 45% of the company’s turnover. All three however are under price control and are likely to remain that way for some time to come.

E Merck: Impressive results from the vitamin king

(Jul 21, 2000)

E Merck has reported an impressive growth of 79% in net profits at Rs 113.61 million for the quarter ended June 30, 2000 over the same period in the last fiscal. This, despite the fact that the sales have grown by 9.85% only. A part of the reason for this growth is that the company had written off VRS expenditure paid to the workers when it closed its Taloja plant. Besides, E Merck repaid a part of its borrowings last year, which has also contributed to the surge in the bottomline.

Impressive results from E Merck

(Apr 25, 2000)

A 10% increase in sales has lead to tripling of profits at the net level.

E Merck's net declines 32%

(Feb 19, 2000)

E Merck has declared impressive results if one takes into account the fact that the company's net profit has been depressed due to extraordinary provisions on account of inter alia Voluntary Retirement Scheme (VRS) payments. Excluding these provisions which add up to Rs.165 million the company's net profit has ctually grown by 28%. Topline growth has been subdued to 7% though in line with the industry growth.

E Merck posts a 12% decline in net

(Oct 26, 1999)

E Merck has posted a 12% decline in profits during the previous quarter ended 30th September 1999. The company has posted a 6% rise in topline. However, the sharp jump in depreciation and the increase in operating expenditure has pulled down margins.

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms